Brain Health & Memory Clinical Trials

Principal Investigator: Brian Appleby, MD

Study Purpose: The goal of the Cleveland Alzheimer's Disease Research Center (CADRC) will be able to increase the speed of research being done on aging related diseases. Our goal is to develop a group of subjects diagnosed with different forms of dementia, including:

• Alzheimer's disease/Mild Cognitive Impairment (MCI)
• Lewy Body Dementia
• We will also enroll cognitively normal individuals with and without a family history of dementia

We will follow patients over time collecting detailed clinical information, biospecimens and imaging data with the goal of better understanding the biology of different forms of dementia. The establishment of a CADRC will also promote additional future research, including therapeutic trials, by having a readily available supply of samples available.

Basic Eligibility Criteria:

• Age 18 and older
• Have AD/MCI/Lewy Body Dementia or are cognitively normal
• Can participate in annual visits with cognitive testing and research blood draw

Study Coordinators: 

• Lyndsi Powell: (216) 464-6204 or Lyndsi.Powell@UHhospitals.org
• Gordon Williams: (216) 464-6434 or Gordon.Williams2@UHhospitals.org
• Susie Sami: (216) 464-6467 orSusie.Sami@uhhospitals.org

Alzheimer’s Clinical Trial Consortium for Down Syndrome (ACTC-DS) - Trial-Ready Cohort - Down Syndrome (TRC-DS)

The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 non-demented adults (ages 35-55) with Down syndrome (DS) into a trial ready cohort (TRC). Participants enrolled in the TRC-DS will undergo longitudinal cognitive and clinical assessment, genetic and biomarker testing, as well as imaging and biospecimen collection. Using these outcome measures, researchers will analyze the relationships between cognitive measures and biomarkers of Alzheimer's disease (AD) to identify endpoints for AD clinical trials in DS that best reflect disease progression .

Vascular reactivity study in dementia patients and age-matched controls

The purpose of this research study is to determine if there are differences in blood flow between people diagnosed with age-related dementia and subjects of a similar age with no diagnosed dementia. The study is being funded by the American Heart Association and the Allen Foundation.

Study Title: A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION717 in Patients with Prion Disease

Principal Investigator: Brian Appleby, MD

Study ID#: Pro0007291

Basic Eligibility Criteria:

• Aged ≥ 18 at the time of informed consent
• A confirmed diagnosis of probable or definite prion disease determined by an independent adjudication committee
• An MRC-PDRS score of ≥ 15 at the time of Screening
• Have a caregiver who is at least 18 years of age, willing to sign an informed consent, accompany the patient to all trial visits (to the best of their ability), willing to be available to the Study Center by phone, and is (in the opinion of the Investigator) likely to remain sufficiently knowledgeable of patient’s condition to respond to inquiries about the patient, such as providing information related to the patient’s cognitive and functional abilities, for the duration of the trial

Foiling Deadly Prions
Can the course of fatal prion diseases be changed by removing the protein before it goes bad?